Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Neoplasm
Phase NA
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial tests how well molecular breast imaging (MBI) works to guide the collection of a breast biopsy in patients with a breast abnormality. Currently, a biopsy is often guided by either ultrasound or mammography in order to ensure that a sample of the correct part of the breast is taken. Sometimes a lesion or part of the lesion cannot be seen on ultrasound or mammography, and, therefore, a biopsy guided with ultrasound or mammography may not be always be accurate. Studies have shown that high resolution MBI may have potential to improve the detection of some breast tumors. This trial uses a new high-resolution MBI system that may help perform a biopsy using MBI.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Sequential Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Procedure: Biopsy of Breast — Undergo biopsy of breast
  • Other: Medical Device Usage and Evaluation — Utilization of the Stereo Navigator accessory
  • Radiation: Scintimammography — Undergo MBI
  • Other: Technetium Tc-99m Sestamibi — Given IV

Primary Outcomes

  • Validation of timeframe (Baseline)
  • Change in image of lesion (Baseline; Up to 6 months)
  • Accuracy of depth estimation by difference in attenuation from opposing views (Baseline; Up to 6 months)
  • Accuracy of depth estimation by difference in apparent lesion size (Baseline; Up to 6 months)
  • Accuracy of depth estimation by triangulation (Baseline; Up to 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-08-26
Completion: 2026-08-26
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Principal Investigators:
  • Katie N. Hunt, M.D. (PRINCIPAL_INVESTIGATOR) - Mayo Clinic in Rochester
Contact Information
Study Contact:
Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu
Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu
Mayo Clinic in Rochester
Katie N. Hunt, M.D.
Mayo Clinic in Rochester
Interventions
  • Procedure: Biopsy of Breast — Undergo biopsy of breast
  • Other: Medical Device Usage and Evaluation — Utilization of the Stereo Navigator accessory
  • Radiation: Scintimammography — Undergo MBI
  • Other: Technetium Tc-99m Sestamibi — Given IV
Study Locations (1 sites)
Mayo Clinic in Rochester, Rochester, Minnesota 55905 United States
Eligibility Criteria
Inclusion Criteria: * PART I: Women aged 18 years or older * PART I: If able to become pregnant, negative pregnancy test within 48 hours prior to MBI biopsy procedure * PART I: Individuals who have previously (within the last 3 years) undergo an MBI study and were found to have at least one breast imaging finding on MBI that was subsequently shown (through additional imaging, biopsy or follow-up) to be benign in nature * PART I: Individuals who have agreed to participate in the study and who have signed the study-specific informed consent * PART II: Women aged 18 years or older * PART II: If able to become pregnant, negative pregnancy test within 48 hours prior to MBI biopsy procedure * PART II: Individuals who have previously (within the last 3 years) undergone an MBI study and were found to have at least one breast imaging finding on MBI that was subsequently shown (through additional imaging, biopsy or follow-up) to be benign or probably benign in nature * PART II: Individuals who had recent conventional imaging work-up including either x-ray mammography, ultrasound, MBI, or MRI of the breast and are found to have at least one breast imaging finding for which biopsy is required or recommended, specifically: * Individuals who have a breast abnormality(ies) on imaging with mammography, ultrasound, MBI, or MRI (as per American College of Radiology \[ACR\] Breast Imaging Reporting and Data System \[BIRADS\] 3, or higher) and requiring imaging follow-up or biopsy confirmation * PART II: Individuals who have agreed to participate in the study and who have signed study-specific informed consent Exclusion Criteria: * PART I: Women who are pregnant * PART I: Women who are currently lactating or discontinued breastfeeding \< 2 months prior to the study * PART I: Age less than 18 years * PART I: Women with breast implant(s) in the breast containing the lesion of interest * PART I: Inability to provide informed consent * PART II: Women who are pregnant * PART II: Women who are currently lactating or discontinued breastfeeding \< 2 months prior to the study * PART II: Age less than 18 years * PART II: Women with breast implant(s) in the breast containing the lesion of interest * PART II: Women who have recently (within the last 3 months) undergone biopsy of the breast finding * PART II: Women who are scheduled for a sentinel node procedure using radioactive Tc-99m within 24 hours of MBI-guided biopsy * PART II: Patients with contraindications for core biopsy and other invasive procedures such as blood coagulation disorders, infection, or who are unwilling to discontinue use of anticoagulant medication prior to the procedure * PART II: Inability to provide informed consent * PART II: Women who have had surgery on the study breast(s) within the past 12 months
Conditions Dry Eye, Glaucoma
Phase PHASE4
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate the preliminary efficacy of the use of insulin eye drops in the control of dry eye disease in patients with topical hypotensors, compared to placebo (artificial tears). The main question aims to answer whether glaucoma patients treated with topical hypotensors could benefit from the use of insulin eye drops for the treatment of dry eye. Participants will be assigned to one of the two treatment arms and will be required to attend four follow-up visits (baseline, 1, 3, and 6 months).

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Insulin — Topical insulin 1UI/ml 4 times a day
  • Drug: Artificial tear — Artificial tears 4 times a day

Primary Outcomes

  • Changes in dry eye symptoms from baseline to 6 months after treatment time (From baseline to 6 months after treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2023-02-08
Completion: 2026-02-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Barbara Burgos Blasco
Principal Investigators:
  • Barbara Burgos Blasco, MD, PhD (PRINCIPAL_INVESTIGATOR) - Hospital Clinico San Carlos
Contact Information
Study Contact:
Barbara Burgos Blasco, MD, PhD
+34 913303000
bburgos171@hotmail.com
Barbara Burgos Blasco
Hospital Clinico San Carlos
Interventions
  • Drug: Insulin — Topical insulin 1UI/ml 4 times a day
  • Drug: Artificial tear — Artificial tears 4 times a day
Study Locations (1 sites)
Hospital Clinico San Carlos, Madrid, Madrid 28040 Spain
Eligibility Criteria
Inclusion Criteria: * Patients who provide written informed consent and who are able and willing to comply with all scheduled study visits and procedures. * Patients ≥ 18 years at the screening visit. * Ocular hypertension or glaucoma controlled with hypotensive treatment * Diagnosis of dry eye Exclusion Criteria: * Uncontrolled glaucoma with expected changes in antihypertensive treatment in the next 6 months * Changes in topical glaucoma treatment in the last 3 months * Severe dry eye requiring immediate treatment * Previous eye surgery, except cataract surgery more than 12 months ago * Laser procedures less than 6 months ago * Other concomitant ocular pathology: scarring disease of the ocular surface, uveitis, infection in the last 90 days, trauma in the last 90 days * Eyelid disorders * Use of contact lenses * Other topical treatment other than dry eye and glaucoma * Patients with a history of allergy or hypersensitivity to the study medication or any of its excipients * Modifications in systemic immunosuppressive treatment in the last 6 months * History of alcohol or drug abuse * Patients who have received an experimental drug or used an experimental medical device in the 30-day period prior to the screening visit. * Systemic pathology (cardiopulmonary pathology, connective tissue disorders, neurological or psychiatric pathology) or situation of the patient that does not allow examination (such as mental or psychomotor retardation). * Any other disease or condition that, at the discretion of the investigator, could constitute a risk to the participant or interfere with the results of the study.
Conditions Diabetes Mellitus, Type 2
Phase Not Applicable
Enrollment 340
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This observational study aims to measure movement behaviours and explore factors influencing these among Bahraini patients with type 2 diabetes. The main objectives are: (i) Measure free-living physical activity and sedentary behaviour with an accelerometer device (ii) Examine associations between movement behaviours and anthropometric and diabetes-related biochemical/clinical parameters (iii) Examine associations between movement behaviours and psychological and environmental determinants that influence movement behaviours (iv) Assess the feasibility and acceptability of the physical activity assessment tools as part of routine clinical practice with clinicians and diabetic patients Participants will be invited to wear an accelerometer device for seven days.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Primary Outcomes

  • Movement behaviour (1 week (duration of the study))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-04-24
Completion: 2025-12-31
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: false
Enrollment: 340 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Royal College of Surgeons in Ireland - Medical University of Bahrain
Collaborators: Ministry of Health, Bahrain, Arabian Gulf University, Bahrain, Royal College of Surgeons, Ireland
Principal Investigators:
  • Ebrahim Rajab, PhD (PRINCIPAL_INVESTIGATOR) - Royal College of Surgeons in Ireland - Medical University Bahrain
Contact Information
Study Contact:
Ebrahim Rajab, PhD
16660122
erajab@rcsi.com
Abeer Alsaweer, MBBS
ASaweer@health.gov.bh
Interventions
N/A
Study Locations (4 sites)
Isa Town Health Centre, Building 10, Road 43, Manama Block 743 Bahrain
Ahmed Ali Kanoo Health Centre, Building 2009, Road 2641, Manama Block 626 Bahrain
Halat Bu Maher Health Centre, Building 2858, Road 1653, Muharraq Block 216 Bahrain
Shaikh Jaber AlSabah Health Centre, Building 6347, Road Nakheel Street, Northern Governorate Block 518 Bahrain
Eligibility Criteria
Inclusion Criteria: * Sex: Men and women are eligible. * Age: Individuals aged 20-75 years old are eligible. * Ethnicity: Bahraini adults of all ethnic groups are eligible for the study. * Type 2 diabetes and glycaemic control: Individuals with controlled type 2 diabetes (i.e. HbA1c \<9 on medication) based on the medical record of each patient's last visit to the health centre for routine follow-up will be eligible if within the last four months. Otherwise, these measurements will be ordered at the first visit to confirm eligibility. * Blood pressure: Individuals whose blood pressure is under moderate control will be eligible - specifically, treated or untreated resting systolic/diastolic pressure \< 160/100 mmHg. * Lipid control: Individuals with fasting triglyceride concentration \< 600 mg are eligible. Exclusion Criteria: * HbA1c \>9% * Type 1 diabetes * Taking insulin * Pregnancy * Non-ambulant or severely incapacitated with any medical condition(s) reducing ability to stand or mobilize. * Currently participating in a study to reduce sedentary behaviour or increase physical activity * Language. Inability to read and understand Arabic or English language. * Inability to give informed consent.
Conditions TNBC - Triple-Negative Breast Cancer
Phase PHASE3
Enrollment 424
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is an open, randomized, controlled, multicenter Phase III clinical study. Eligible subjects were randomly assigned 1:1 to albumin-paclitaxel plus carboplatin and carrilizumab with or without famitinib neoadjuvant therapy. Stratification was performed at randomization according to the following factors: clinical stage of the tumor (stage II; Stage III) and CD8 expression status (IHC ≥10%, \< 10%). Subjects who have completed neoadjuvant therapy and are suitable for surgery are required to undergo surgery. Subjects in the experimental group will continue to receive carrilizumab and famitinib until one year from the start of neoadjuvant therapy, and subjects in the control group will continue to receive carrilizumab until one year from the start of neoadjuvant therapy. Subjects who completed neoadjuvant therapy were required to undergo imaging efficacy evaluation according to RECIST1.1 before surgery; subjects suitable for surgery received surgical treatment, and pathological evaluation of tumor efficacy was performed after surgery. During the study treatment, if the subjects show disease progression, toxicity intolerance, withdrawal of informed consent, or the investigator determines that medication must be terminated, the study treatment will be terminated, and follow-up will continue, including disease recurrence and metastasis and safety follow-up. Participants who complete surgical treatment will be followed for at least 2 years for event-free survival (EFS), disease-free survival (DFS), distant metastasis-free survival (DDFS), and safety assessment. Safety data should be collected from the signing of the informed consent until 28 days after the end of the study.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Camrelizumab Plus Chemotherapy and Famitinib — camrelizumab+chemotherapy (Albumin-paclitaxel plus carboplatin)+Famitinib
  • Drug: Camrelizumab Plus Chemotherapy — Camrelizumab Plus Chemotherapy

Primary Outcomes

  • Pathological complete response (pCR) rate (Up to approximately 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-08-20
Completion: 2027-08-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 424 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Contact Information
Study Contact:
chen li, MD
+86-021-64175590
chen_li@fudan.edu.cn
Zhi-Ming Shao, MD
86-21-641755901105
zhimingshao@yahoo.com
Breast cancer institute of Fudan University Cancer Hospital
Lei Fan, MD
86-21-641755901105
cmchen@medmail.com.cn
Breast cancer institute of Fudan University Cancer Hospital
Interventions
  • Drug: Camrelizumab Plus Chemotherapy and Famitinib — camrelizumab+chemotherapy (Albumin-paclitaxel plus carboplatin)+Famitinib
  • Drug: Camrelizumab Plus Chemotherapy — Camrelizumab Plus Chemotherapy
Study Locations (2 sites)
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai Municipality 200032 China
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai Municipality 200032 China
Eligibility Criteria
Inclusion Criteria: * Inclusion Criteria: ECOG Performance Status of 0-1. Early or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression). Tumor stage: II-III. Adequate hematologic and organ function. Must be willing to use an adequate method of contraception for the course of the study. Exclusion Criteria: * Has a history of breast cancer. Has a history of invasive malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. Has received prior chemotherapy, targeted therapy, and radiation therapy within the past 12 months. Has received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1), anti-programmed death - ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated antigen-4 \[CTLA-4\]. Has a diagnosis of immunodeficiency or autoimmune diseases. Has received any form of immunosuppressive therapy within 4 weeks prior to the first dose of study treatment. Severe pulmonary or cardiac disease. Known active hepatitis C virus, or known active hepatitis B virus. History of organ or bone marrow transplantation. Pregnant or breast-feeding women. Patients who have previously received VEGFR-like small molecule tyrosine kinase inhibitors (such as famitinib, sorafenib, Sunitinib, regorafenib, etc.) (except bevacizumab); Urine routine indicated urinary protein ≥2+ and confirmed urinary protein quantity \> 1g at 24h;
Conditions Mental Health
Phase NA
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The mental health of adolescents in the United States has seen a steep decline, roughly coinciding with the increasing popularity of social media and smartphones. But does social media have a causal impact on the mental health of adolescents or are concerns about the effect of social media on kids a form of public hysteria? In this study, the investigators will conduct the first field experiment in 10-14-year-olds to examine whether, how, and for whom social media harms mental health.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Restricted Social Media — Participants (N = 500) will be randomly assigned to either have no study-imposed restrictions on social media use (naturalistic social media condition) or have no access to social media apps on their phones (restricted social media condition). This manipulation will last three months, after which both groups will have no study-imposed restrictions on social media for three more months.

Primary Outcomes

  • Revised Child Anxiety and Depression Scale (RCADS-25): Total Score (Baseline, three months, and six months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-29
Completion: 2028-06-01
Eligibility
Age: 10 Years and older
Sex: ALL
Volunteers: true
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Georgetown University
Collaborators: National Institutes of Health (NIH)
Contact Information
Study Contact:
Kostadin Kushlev, PhD
804-585-4385
kk1199@georgetown.edu
Kostadin Kushlev, PhD
kk1199@georgetown.edu
Georgetown University
Interventions
  • Behavioral: Restricted Social Media — Participants (N = 500) will be randomly assigned to either have no study-imposed restrictions on social media use (naturalistic social media condition) or have no access to social media apps on their phones (restricted social media condition). This manipulation will last three months, after which both groups will have no study-imposed restrictions on social media for three more months.
Study Locations (1 sites)
Georgetown University, Washington D.C., District of Columbia 20057 United States
Eligibility Criteria
Inclusion Criteria: 1. is an adolescent who is between the ages of 10 and 14; 2. is an adolescent whose parents have decided to buy them their first smartphone; 3. is an adolescent both of whose parents/guardians consent for them to be in the study; 4. is an adolescent who assents to be in the study; 5) is an adolescent who speaks and reads English sufficiently to complete surveys and provide informed consent. Exclusion Criteria: 1. is an adolescent who has severe developmental problems (e.g., autism, severe language delay); 2. is an adolescent who is currently or has ever been diagnosed with severe or moderately severe mental illness; 3. is an adolescent who is currently or has ever experienced suicidal ideation.
Conditions Cardiometabolic Syndrome, Physical Inact...
Phase NA
Enrollment 340
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Lower attainment of cardiovascular health (CVH), indicated by the American Heart Association's Life's Simple 7 (LS7; physical activity, diet, cholesterol, blood pressure, body mass index, smoking, glycemia) and Life's Essential 8 (LE8; LS7+sleep) metrics, is a major contributor to Black men having the shortest life-expectancy of any non-indigenous race/sex group. Unfortunately, a paucity of literature exists on interventions aimed at improving CVH among Black men. The team of clinician scientists and community partners co-developed a community-based lifestyle intervention titled Black Impact: a 24-week intervention for Black men with less-than-ideal CVH (\<4 LS7 metrics in the ideal range) with 45 minutes of weekly physical activity, 45 minutes of weekly health education, and engagement with a health coach, group fitness trainer, and community health worker. Single-arm pilot testing of the intervention (n=74) revealed high feasibility, acceptability, and retention and a 0.93 (95% confidence interval: 0.40, 1.46, p\<0.001) point increase in LS7 score at 24 weeks. Secondary outcomes included improvements in psychosocial stress (i.e., perceived stress, depressive symptoms), patient activation, and social needs. Thus, robustly powered clinical trials are needed to determine the efficacy of Black Impact and to evaluate the underlying interpersonal and molecular pathways by which Black Impact improves psychosocial stress and CVH. Thus, the investigators propose a randomized, wait-list controlled trial of Black Impact. This novel, community-based intervention to provide a scalable model to improve CVH and psychosocial stress at the population level and evaluate the biological underpinnings by which the intervention mitigates cardiovascular disease risk. The proposed study aligns with American Heart Association's commitment to addressing CVH equity through innovative, multi-modal solutions.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Black Impact Intervention — The Black Impact intervention is an academic-community-government partnership adapted from the Diabetes Prevention Program and American Heart Association Check, Change, Control programs based on stakeholder feedback and to afford incorporation of additional evidence-based strategies for influencing target outcomes. The intervention is a 24-week community-based lifestyle intervention to improve cardiovascular health among Black men. Each participant will be assigned to a group with \>5 participants based on participant proximity to a central community meeting location. Each team will be guided weekly by a health coach who delivers content and coaching around the lifestyle intervention modeled on the diabetes prevention program and check, change, control blood pressure program, a community health worker who helps to address social needs and connects participants to primary care services, and a trainer who leads physical activity. Teams meet for 90 minutes per week.

Primary Outcomes

  • Cardiovascular Health (24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-08-24
Completion: 2027-03-31
Eligibility
Age: 18 Years and older
Sex: MALE
Volunteers: false
Enrollment: 340 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ohio State University
Collaborators: American Heart Association
Principal Investigators:
  • Joshua Joseph, MD (PRINCIPAL_INVESTIGATOR) - Ohio State University
Contact Information
Study Contact:
Sean Matambo
773-683-9241
Sean.Matambo@osumc.edu
Luiza Reopell
614-653-8213
Luiza.Reopell@osumc.edu
Sean Matambo
773-683-9241
Sean.Matambo@osumc.edu
The Ohio State University
Interventions
  • Behavioral: Black Impact Intervention — The Black Impact intervention is an academic-community-government partnership adapted from the Diabetes Prevention Program and American Heart Association Check, Change, Control programs based on stakeholder feedback and to afford incorporation of additional evidence-based strategies for influencing target outcomes. The intervention is a 24-week community-based lifestyle intervention to improve cardiovascular health among Black men. Each participant will be assigned to a group with \>5 participants based on participant proximity to a central community meeting location. Each team will be guided weekly by a health coach who delivers content and coaching around the lifestyle intervention modeled on the diabetes prevention program and check, change, control blood pressure program, a community health worker who helps to address social needs and connects participants to primary care services, and a trainer who leads physical activity. Teams meet for 90 minutes per week.
Study Locations (1 sites)
The Ohio State University, Columbus, Ohio 43202 United States
Eligibility Criteria
Inclusion Criteria: * The inclusion criteria are: 1) Black men (self-report); 2) adult age 18 years or older; 3) Life's Essential 8 total average score \< 80; 4) English speaking; and 5) lives in Metropolitan Columbus, Ohio. Exclusion Criteria: * healthcare provider-imposed limitations on physical activity.
Conditions Depression, Epilepsy
Phase NA
Enrollment 16
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The specific aim of this study is to compare simultaneous assessment of gastric emptying and gastric accommodation in response to a caloric meal In patients who have previously undergone activation of left cervical VNS for the treatment of medication-resistant depression. Our hypothesis is that cervical VNS increases gastric accommodation and accelerates gastric emptying compared to a bank of healthy control data.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Device: Vagal nerve stimulant — Vagus nerve stimulation involves using a device to stimulate the vagus nerve with electrical impulses. The implanted electrodes transmit electrical impulses travel to areas of the brain to treat conditions (intractable epilepsy, depression) and also send electrical impulses to the stomach.

Primary Outcomes

  • Gastric emptying T1/2 (during 4 hour gastric emptying test)
  • Gastric accommodation (during first 1 hour of gastric emptying test)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-01
Completion: 2027-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 16 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Collaborators: University of Minnesota
Principal Investigators:
  • Michael Camilleri (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
Kathryn Vera, PhD
612-625-5018
giero002@umn.edu
University of Minnesota
Paula Carlson, BS
507-284-2511
carlson.paula@mayo.edu
Mayo Clinic in Rochester
John Osborn, PhD
Mayo Clinic in Rochester
Interventions
  • Device: Vagal nerve stimulant — Vagus nerve stimulation involves using a device to stimulate the vagus nerve with electrical impulses. The implanted electrodes transmit electrical impulses travel to areas of the brain to treat conditions (intractable epilepsy, depression) and also send electrical impulses to the stomach.
Study Locations (2 sites)
University of Minnesota, Minneapolis, Minnesota 55455 United States
Mayo Clinic in Rochester, Rochester, Minnesota 55905 United States
Eligibility Criteria
General criteria 1. Participant must be at least 18 years old. 2. Participant must have the capacity to provide written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization. 3. Participant is diagnosed with drug Resistant Epilepsy and previously underwent implantation of VNS. and/or 4. Participant is diagnosed with treatment-refractory depression and previously underwent implantation of VNS. 5. Participant has completed the REVEAL CSP and has been stabilized by their care team on a stable VNS setting 6. Apart from epilepsy or depression, participant should be medically and neurologically stable. 7. Participant is able to complete regular office visits and telephone appointments including the imaging session in accordance with the study protocol requirements. 8. Participant that is of childbearing potential must be adequately protected from conception or willing to use an acceptable method of birth control over the entire study duration (acceptable birth control includes abstinence, barrier methods, hormonal methods, sterilization and fertility awareness). 9. Participant must be enrolled in an active health insurance plan that will cover the costs associated with standard health care services and injuries. Exclusion Criteria: GENERAL criteria 1. Participant has a prior implantable stimulation device other than a VNS device for the clinical indication of refractory focal Epilepsy or for depression. 2. Participant currently uses or during the study is expected to use short-wave diathermy, microwave, diathermy, or therapeutic ultrasound diathermy. 3. Participant has a diagnosis of Substance Use Disorder as defined by DSM-5 without sustained remission of 12 months or longer. 4. Patient participated in another drug or device trial within the preceding 30 days (other than REVEAL studies). 5. Participant has been hospitalized for a psychiatric condition within the preceding 6 months or has had a history of psychosis within the preceding two years (excluding post-ictal psychosis). 6. Participant has experienced unprovoked status epilepticus in the preceding year. 7. Participant is not able or willing to use their dominant arm, or either upper arm circumference is greater than 50 cm. 8. Any other clinical reasons deemed by the investigators of the study for which the participant would not be an appropriate candidate for the study, such as peripheral vascular disease, Raynaud's phenomenon, orthostatic hypotension (OH), postural orthostatic tachycardia syndrome (POTS), uncontrolled obstructive sleep apnea (OSA), chronic obstructive pulmonary disease (COPD), or uncontrolled diabetes or pregnancy 9. Participant with vocal cord paralysis 10. Participant cannot speak and read English. 11. Participant is pregnant. 12. Prohibited Therapy During Study Period: We will exclude patients on immunosuppressants, beta blockers, anticholinergics, and clonidine. Consultation with primary providers and amending some of these therapies may be allowed only if clinically indicated. In that case, participants will have to be stable on their new medication for at least one month prior to implant. 13. A body weight of over 350 pounds or 159 kilograms due to equipment limitations used in the measurements of gastric accommodation and emptying. 14. An inability to eat eggs whether due to an allergy, intolerance, or strong dislike. The gastric emptying test meal contains eggs that are labeled with radioisotope. Other food substitutions for the toast, butter and milk may be made only if prior approval is given by Dr. Camilleri. 15. Any other factor that may impact participant safety or compliance as per PI. Since participants with pVNS will be recruited from the CSP study at U Minnesota, it is important to specify the inclusion and exclusion criteria for participants with drug-resistant epilepsy or drug-resistant depression who entered the CSP study: Inclusion Criteria for Participants With Major Depressive Disorder That Have a Previously Implanted VNS Device 1. Participant must be at least 18 years old. 2. Participant must have the capacity to provide written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization. 3. Participant must be enrolled in an active health insurance plan that will cover the costs associated with standard health care services and injuries. 4. Participant must have been previously implanted with a VNS device for the clinical indication of Major Depressive Disorder (MDD). 5. Participant must have a score on the baseline administration of the Montgomery-Åsberg Depression Rating Scale (MADRS) of ≥ 22. 6. Participant must be able and willing to complete the evaluations and procedures described in the study protocol. 7. Participant must be able and willing to follow the stipulations regarding concomitant medications and excluded medications described in section 5.3 of the study protocol. 8. Participant that is of childbearing potential must be adequately protected from conception or willing to use an acceptable method of birth control over the entire study duration (acceptable birth control includes abstinence, barrier methods, hormonal methods, sterilization and fertility awareness). Exclusion Criteria for Participants With Major Depressive Disorder That Have a Previously Implanted VNS Device 1. Participant has a prior implantable stimulation device, other than a VNS device for the clinical indication of Major Depressive Disorder (MDD). 2. Participant currently uses or is expected during the study to use short-wave diathermy, microwave, diathermy, or therapeutic ultrasound diathermy. 3. Participant is judged by the investigator to be acutely suicidal (e.g. has made specific plans or preparations to commit suicide or as indicated by the Sheehan Suicidality Tracking Scale) within the last 30 days prior to study enrollment. 4. Participant has made a suicide attempt within the previous 6 months from study enrollment. 5. Participant has a history of one or more schizophrenia-spectrum or other psychotic disorders including schizophrenia, schizoaffective disorder, delusional disorder, or a current or lifetime major depressive episode that includes psychotic features (commonly referred to as psychotic depression) according to the MINI criteria. 6. Participant has a history of significant borderline or severe personality disorder as determined by clinical judgment. 7. Participant has an active primary diagnosis of obsessive-compulsive, eating, or post-traumatic stress disorder based on the MINI criteria. 8. Participant has a diagnosis of Substance Use Disorder as defined by DSM-5 without sustained remission of 12 months or longer. 9. Participant has a presence of any type of dementia, major neurocognitive disorder, or cognitive or psychiatric deficit as determined by clinical judgment. 10. Participant has a history of rapid cycling bipolar disorder I or II. 11. Participant currently receives treatment with another investigational device or investigational drug other than the REVEAL study (or a REVEAL ancillary project or sub-study) or has participated in another drug or device trial within the preceding 30 days before enrollment. 12. Participant is not able or willing to use their dominant arm, or either upper arm circumference is greater than 50 cm. 13. Participant does not speak English. 14. Participant is pregnant. 15. Any other clinical reasons deemed by the investigators of the study for which the participant would not be an appropriate candidate for the study, such as peripheral vascular disease, Raynaud's phenomenon, orthostatic hypotension (OH), postural orthostatic tachycardia syndrome (POTS), uncontrolled obstructive sleep apnea (OSA), chronic obstructive pulmonary disease (COPD), or uncontrolled diabetes. Inclusion Criteria for Participants With Drug Resistant Epilepsy That Have a Previously Implanted VNS Device 1. Participant must be at least 18 years old. 2. Participan
Conditions Morbid Obesity, Type2diabetes, Sleep Apn...
Phase Not Applicable
Enrollment 35
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This observational study aims to learn about the correlation between the improving comorbidities associated with obesity after MGB (Mini-Gastric Bypass) surgery and changes in body composition in morbidly obese patients. The main questions it aims to answer are: To study the correlation between the improving comorbidities associated with obesity after MGB(Mini-Gastric Bypass) surgery and changes in body composition. Other objectives are: * Changes in the parameters of the metabolic syndrome after surgery * Changes in the cardiovascular risk biomarkers after metabolic surgery * Emergence in complications arising out of surgery requiring any intervention or causing a prolonged hospital stay, or requiring additional outpatient visits. Type of Study: An observational study in which participants with morbid obesity will undergo mini-gastric bypass surgery as per routine protocol. No separate experimental interventions will be done in the study for the participants.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Mini gastric bypass surgery — Mini gastric bypass surgery is a common metabolic or bariatric surgery done world wide for patients suffering from morbid obesity not managed by non surgical modalities of treatment.

Primary Outcomes

  • To study the correlation between the improving comorbidities associated with obesity after MGB(Mini-Gastric Bypass) surgery and changes in body composition. (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-09-01
Completion: 2027-03-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 35 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: All India Institute of Medical Sciences, Bhubaneswar
Principal Investigators:
  • Prakash K Sasmal, MS, FACS (PRINCIPAL_INVESTIGATOR) - All India Institute of Medical Sciences, Bhubaneswar, India
Contact Information
Study Contact:
Prakash K Sasmal, MS, FACS
+91 9438884255
drpksasmal@gmail.com
Velugoti Sai Pradeep, MBBS
+91 6300465988
saiprad372@gmail.com
Prof. Prakash Kumar Sasmal, MS, FNB (MAS), FACS
+91 9438884255
drpksasmal@gmail.com
All India Institute of Medical Sciences
Interventions
  • Procedure: Mini gastric bypass surgery — Mini gastric bypass surgery is a common metabolic or bariatric surgery done world wide for patients suffering from morbid obesity not managed by non surgical modalities of treatment.
Study Locations (1 sites)
All India Institute of Medical Sciences, Bhubaneswar, Odisha 751019 India
Eligibility Criteria
Inclusion Criteria: * All patients undergoing laparoscopic MGB surgery for morbid obesity and it's associated comorbidities Exclusion Criteria: * Patients not giving consent for the study * All patients who were undergoing a redo-procedure for recurrence were excluded from the study
Conditions Diabetes Mellitus, Type 2
Phase PHASE2
Enrollment 300
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The aim of the study is to determine whether NLRP3 inhibition with dapansutrile represents a new pharmacological option for diabetes management with potential as an anti-inflammatory agent to also address micro- and macro-vascular risk and complications from diabetes.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Dapansutrile — Patients receive investigational product.
  • Drug: Placebo — Patients receive placebo.

Primary Outcomes

  • Change in HbA1c in blood of patients for dapansutrile compared to placebo (two time assessment at baseline and week 26)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-07-09
Completion: 2028-07-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Marc Donath
Collaborators: European Union, State Secretariat for Education Research and Innovation, Switzerland, Olatec Therapeutics, Inc., Departement Klinische Forschung Universität Basel, CTU Kantonsspital Baden
Principal Investigators:
  • Marc Y. Donath, Prof. (STUDY_CHAIR) - Kantonsspital Baden, Switzerland
Contact Information
Study Contact:
Marc Y. Donath, Prof.
+41 61 265 50 78
marc.donath@umontreal.ca
Markus Veit
+41 56 486 25 14
markus.veit@ksb.ch
Nathalie Esser, ass. Prof.
+32 4 323 72 37
nathalie.esser@chuliege.be
CHU de Liege
Interventions
  • Drug: Dapansutrile — Patients receive investigational product.
  • Drug: Placebo — Patients receive placebo.
Study Locations (6 sites)
CHU de Liege, Liège, 4000 Belgium
Hopital Lariboisiere, Paris, Île-de-France Region 75010 France
Hopital Bichat, Paris, Île-de-France Region 75018 France
Deutsches Zentrum für Diabetesforschung Düsseldorf, Düsseldorf, Nordrhein-Westphalen 40225 Germany
University Hospital Basel, Basel, Basel 4031 Switzerland
Kantonsspital Olten, Olten, Canton of Solothurn 4600 Switzerland
Eligibility Criteria
Inclusion Criteria: * Diagnosis of type 2, Diabetes mellitus as defined by the criteria of the American Diabetes Association (ADA) Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (see Appendix 1) and recognized by the World Health Organization (WHO, 2019), for at least 3 months prior to the Baseline Visit/Day 1 * HbA1c value of ≥ 7.7% to ≤ 11.0% at the Screening Visit. * High-sensitivity C-reactive protein (hsCRP) ≥ 1.5 mg/L at the Screening Visit. * Body mass index (BMI) ≥25 to ≤ 40 kg/m2 at the Screening Visit * Acceptable overall medical condition to safely participate in the study and complete all study procedures (particularly with regard to cardiovascular, renal, and hepatic conditions), in the opinion of the Investigator Exclusion Criteria: * Diagnosis of type 1 diabetes mellitus * HbA1c value of ≤ 7.5% or ≥ 10.5% at the Baseline Visit/Day 1, as determined at point of care (local laboratory) * Use of thiazolidinediones (glitazones), pramlintide, or short-acting insulin/insulin analogues (as bolus or premixed insulin) within 12 weeks prior to the Screening Visit * Less than 80% compliance in taking investigational medicinal product by pill count during the Run-In Period, as assessed at the Baseline Visit/Day 1 * Significant weight loss (\> 5 kg) in the 12 weeks prior to the Screening Visit * Systolic blood pressure (BP) ≥ 160 mmHg, diastolic BP ≥ 100 mmHg, or resting heart rate (HR) ≥ 100 beats/minute at the Screening Visit * Previous myocardial infarction, any cardiac surgery

RIVER At Home Ketamine Protocols

NCT06070766
Recruiting
Conditions Chronic Condition, Chronic Pain, Chronic...
Phase Not Applicable
Enrollment 50000
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Multiple site studies with the recruitment of other sub-investigators and sites. It's sobering to consider how chronic illness makes us more vulnerable to suicidal thoughts and behavior. However, the existence of multiple risk factors also means that there are numerous ways to intervene. Addressing and improving even one risk area will reverberate and improve other areas and the quality of life. RIVER Foundation is completing a 500-participant pilot study researching the safety of oral and nasal ketamine at home with no therapy. The pilot study examined three psychological scales: P.H.Q. 9, G.A.D. 7, and PCL5 scores. The interim report will be available in Nov 2023 with a final report in June 2024. The lack of knowledge for the average medical practitioner makes ketamine a boutique medicine, often costly and unaffordable to those in need. Yet daily medical providers are eliminating ketamine as a choice in the treatment of chronic conditions. The pilot study demonstrated the who, and where. The who, was adults with a chronic condition. The pilot study demonstrated the majority of those who could use ketamine are not receiving it due to cost. According to the 500-participant study, ketamine is safe and effective for at-home use thus demonstrating the where (at home with no supervision).

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Interventions / Regimen

  • Drug: Ketamine — The use of ketamine in chronic conditions.

Primary Outcomes

  • Mental Health PHQ9 (Through study completion, an average of 5 years)
  • Mental Health GAD7 (Through study completion, an average of 5 years)
  • Mental Health PCL5 (Through study completion, an average of 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-10-01
Completion: 2029-04-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: RIVER Foundation
Principal Investigators:
  • Dharma Rose, D.O. M.S. (PRINCIPAL_INVESTIGATOR) - RIVER Foundation
  • Frank Yurseak, Ph.D. (STUDY_CHAIR) - RIVER Foundation
  • Jeffery Newton (PRINCIPAL_INVESTIGATOR) - RIVER Foundation
Contact Information
Study Contact:
Ed Lesofski, M.S.
406-431-4890
ed@riverofchange.org
James Taggart, M.D.
415--713-6554
info@riverofchange.org
Ed Lesofski, MS
406-431-4890
ed@riverofchange.org
RIVER Foundation
Interventions
  • Drug: Ketamine — The use of ketamine in chronic conditions.
Study Locations (2 sites)
RIVER Foundation, Bigfork, Montana 59911 United States
RIVER Telehealth, Helena, Montana 59601 United States
Eligibility Criteria
Inclusion Criteria: Must have an identifiable chronic condition. Exclusion Criteria: Healthy Population
Conditions Depression, Unipolar, Eveningness
Phase NA
Enrollment 162
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this prospective randomised controlled trial is to examine the effects of cognitive behavioural therapy and bright light therapy in youths with unipolar depression and evening chronotype. The main questions it aims to answer are: 1. What is the efficacy of CBT-D and CBT-D plus bright light therapy in reducing depression severity in adolescents with depression and eveningness? 2. What are the effects of CBT-D and CBT-D plus bright light therapy on the subjective and objective sleep and circadian measures, as well as the quality of life, daytime symptoms, and functioning (e.g., sleepiness, fatigue)? Participants will participate in 8 weekly group sessions of CBT-D intervention based on the well-established CBT elements for treating depression. Concurrently participants will also be asked to wear a portable light device at home for 30 minutes daily for seven weeks, starting from the second week of the group intervention. Participants in the CBT-D only group will receive a placebo light via the device, whereas participants in the CBT-D plus light therapy group will receive the active bright light via the device.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Cognitive Behavioural Therapy for Depression — Consists of 8 weekly sessions (group-based, 90-min, 4-6 adolescents in each group). The intervention focuses on addressing depression, with the components such as psycho-education on depression, self-monitoring, behavioural activation, and cognitive restructuring (addressing negative and irrational thoughts often associated with depression in adolescents), relaxation techniques, and relapse prevention.
  • Device: Bright Light Therapy — Participants will undergo daily morning light therapy by wearing a validated portable light emitting device (i.e., Re-Timers: https://www.re-timer.com/) at home for 30 minutes. Participants will receive bright blue-green light (500 nm, 506 lux).

Primary Outcomes

  • Change in Assessor-rated Depressive Symptoms (Baseline and one-week post-treatment/Week 9 for all participants, and post-treatment 1-month follow-up and post-treatment 6-month follow-up for the participants in the treatment groups)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-10-31
Completion: 2026-10-20
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 162 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Hong Kong
Collaborators: Chinese University of Hong Kong
Contact Information
Study Contact:
Shirley X Li, DClinPsy
+852 39177035
shirley.li@hku.hk
Shirley Xin Li, Dr
+852 3917-7035
shirley.li@hku.hk
Sleep Research Clinic & Laboratory, Department of Psychology, The University of Hong Kong
Interventions
  • Behavioral: Cognitive Behavioural Therapy for Depression — Consists of 8 weekly sessions (group-based, 90-min, 4-6 adolescents in each group). The intervention focuses on addressing depression, with the components such as psycho-education on depression, self-monitoring, behavioural activation, and cognitive restructuring (addressing negative and irrational thoughts often associated with depression in adolescents), relaxation techniques, and relapse prevention.
  • Device: Bright Light Therapy — Participants will undergo daily morning light therapy by wearing a validated portable light emitting device (i.e., Re-Timers: https://www.re-timer.com/) at home for 30 minutes. Participants will receive bright blue-green light (500 nm, 506 lux).
Study Locations (1 sites)
Sleep Research Clinic & Laboratory, Department of Psychology, The University of Hong Kong, Hong Kong, Hong Kong
Eligibility Criteria
Inclusion Criteria: 1. Chinese aged 12-20 years old. 2. Written informed consent of participation into the study is given by the participant and his/her parent or guardian (for those aged under 18). 3. Being able to comply with the study protocol. 4. Having a DSM-5 diagnosis of depressive disorders. 5. Having a score of ≥ 40 on Children's Depression Rating Scale (CDRS-R). 6. Having a score of ≤ 41 on Horne-Östberg Morning-Eveningness Questionnaire (MEQ; classified as evening chronotype). 7. Having a sleep onset time of 11:15pm or later for 12 year olds, 11:30pm or later for 13-14 year olds, and 12:00pm or later for 15-20 years at least 3 nights per week in the past 3 months. Exclusion Criteria: 1. A current diagnosis of substance abuse or dependence; a current or past history of manic or hypomanic episode, schizophrenia spectrum disorders, neurodevelopmental disorders, organic mental disorders, or intellectual disabilities. 2. Initiation of and change of medication that may interfere with circadian rhythm within past 3 months (e.g., lithium, exogenous melatonin, melatonergic antidepressants). 3. In the opinion of the research clinician, having a clinically significant suicidality (presence of suicidal ideation with a plan or an attempt). 4. Having been enrolled in any other clinical trial investigational products within one month at the entry of the study. 5. Initiation of or change in antidepressant medication within past 3 months. 6. Having been or is currently receiving any structured psychotherapy. 7. With hearing or speech deficit. 8. Night shift worker. 9. Trans-meridian flight in the past 1 month and during intervention. 10. Presence of an eye disease (e.g., retinal blindness, severe cataract, glaucoma).
Conditions Breast Cancer Female, Endocrine Therapy
Phase Not Applicable
Enrollment 1200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To observe and evaluate the clinical efficacy and safety of continuous use of OFS for premenopausal patients with early breast cancer after 5 years use of OFS. This study is a multicenter, prospective, observational, non randomized controlled, open-label real world study based on hospital medical record system data, aimed at evaluating the benefits of continuing to use OFS after 5 years of use. The retrospective analysis plan includes patient data from September 1, 2023 to September 1, 2026. Join two cohorts: the continued use group and the discontinued use group after 5 years of OFS, respectively.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: OFS continues to use group after 5 years use — Patients included in the group continued or discontinued to use goserelin or leuprolide after 5 years use.
  • Diagnostic Test: Immunohistochemical detection of HR status — Enrolled patients must be HR-positive premenopausal breast cancer patients

Primary Outcomes

  • invasive disease-free survival (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-09-01
Completion: 2028-09-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 1200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hongmei Zheng, PhD
Principal Investigators:
  • Hongmei Zheng, Doctor (PRINCIPAL_INVESTIGATOR) - Study Principal Investigator
Contact Information
Study Contact:
Hongmei Zheng, Doctor
18971624606
zhenghongmeicj@163.com
Xinhong Wu, Doctor
18602726300
wuxinhong_9@sina.com
xinhong wu, Dr
+8618602726300
wuxinhong_9@sina.com
Wu Xinhong
Interventions
  • Drug: OFS continues to use group after 5 years use — Patients included in the group continued or discontinued to use goserelin or leuprolide after 5 years use.
  • Diagnostic Test: Immunohistochemical detection of HR status — Enrolled patients must be HR-positive premenopausal breast cancer patients
Study Locations (1 sites)
Wu Xinhong, Wuhan, Hubei China
Eligibility Criteria
Inclusion Criteria: * Diagnosed with early primary breast cancer * Female aged 18-60 years (including 18 year and 60 year) * Hormone receptor (HR) positive HER2 negative * Receive 5 years of OFS treatment * ECOG score 0-1 * Voluntarily join this study and sign the informed consent form; * The researcher believes that it can benefit. Exclusion Criteria: * The patient is receiving treatment that affects OFS at the same time The patient has received OFS treatment for less than 5 years * Central nervous system metastases with known obvious symptoms, such as headache, cerebral edema, blurred vision * Invasive metastases with known obvious symptoms * Invasive metastases with known obvious symptoms * Doctors think it is not suitable for inclusion